Cholesterol metabolism and vascular disease
Cholesterol metabolism and vascular disease
Cholesterol is packaged into lipoprotein particles in the liver and intestine and transported to peripheral tissues for normal cellular function. Reverse cholesterol transport is the mechanism by which excess cholesterol is transported back to the liver and is facilitated by high-density lipoproteins (HDLs). Increased plasma concentrations of cholesterol within the low-density lipoprotein (LDL) contribute to atherosclerotic vascular disease that commonly affects the coronary, cerebral and peripheral vascular circulation. Incontrovertible evidence now supports the use of the ‘statin’ class of drugs to decrease vascular disease. Statins inhibit hepatic cholesterol synthesis, increase hepatic low-density lipoprotein cholestrol (LDLc) receptor expression and consequently decrease plasma LDLc, to reduce risk of myocardial infarction in people at widely varying risk of heart disease. At present, there is limited evidence to support the use of drugs that modify high-density lipoprotein cholesterol (HDLc) to reduce risk of heart disease.
cholesterol, atherosclerotic vascular disease, randomized trials
Olufadi, R.
c015aa43-82a7-4741-b952-7871aa651bf6
Wild, S.H.
eb23a87e-b8da-4f3f-8dab-e02e7b5104aa
Byrne, C.D.
1370b997-cead-4229-83a7-53301ed2a43c
15 September 2009
Olufadi, R.
c015aa43-82a7-4741-b952-7871aa651bf6
Wild, S.H.
eb23a87e-b8da-4f3f-8dab-e02e7b5104aa
Byrne, C.D.
1370b997-cead-4229-83a7-53301ed2a43c
Record type:
Book Section
Abstract
Cholesterol is packaged into lipoprotein particles in the liver and intestine and transported to peripheral tissues for normal cellular function. Reverse cholesterol transport is the mechanism by which excess cholesterol is transported back to the liver and is facilitated by high-density lipoproteins (HDLs). Increased plasma concentrations of cholesterol within the low-density lipoprotein (LDL) contribute to atherosclerotic vascular disease that commonly affects the coronary, cerebral and peripheral vascular circulation. Incontrovertible evidence now supports the use of the ‘statin’ class of drugs to decrease vascular disease. Statins inhibit hepatic cholesterol synthesis, increase hepatic low-density lipoprotein cholestrol (LDLc) receptor expression and consequently decrease plasma LDLc, to reduce risk of myocardial infarction in people at widely varying risk of heart disease. At present, there is limited evidence to support the use of drugs that modify high-density lipoprotein cholesterol (HDLc) to reduce risk of heart disease.
Text
a0002264.pdf
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Published date: 15 September 2009
Keywords:
cholesterol, atherosclerotic vascular disease, randomized trials
Identifiers
Local EPrints ID: 72804
URI: http://eprints.soton.ac.uk/id/eprint/72804
PURE UUID: 451d115d-a4b1-4bb5-a3c1-55253c3b43c8
Catalogue record
Date deposited: 23 Feb 2010
Last modified: 14 Mar 2024 02:43
Export record
Altmetrics
Contributors
Author:
R. Olufadi
Author:
S.H. Wild
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics